

1 **SUPPLEMENTARY APPENDIX.**

2 Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced
3 immunity from seasonal human coronavirus humoral responses

4 Eric D. Laing^{1*}, Spencer L. Sterling^{1,2}, Stephanie A. Richard^{2,3}, Nusrat J. Epsi^{2,3}, Si'Ana
5 Coggins^{1,2}, Emily C. Samuels^{1,2}, Shreshta Phogat^{1,2}, Lianying Yan^{1,2}, Nicole Moreno^{2,3}, Christian
6 L. Coles^{2,3}, Matthew Drew⁴, Jennifer Mehalko⁴, Caroline E. English^{2,3}, Scott Merritt^{2,3,5}, Katrin
7 Mende^{2,3,5}, Vincent J. Munster⁶, Emmie de Wit⁶, Kevin K. Chung⁷, Eugene V. Millar^{2,3}, David R.
8 Tribble³, Mark P. Simons^{1,3}, Simon D. Pollett^{2,3}, Brian K. Agan^{2,3}, Dominic Esposito⁴, Charlotte
9 Lanteri², G. Travis Clifton⁵, Edward Mitre¹, Timothy H. Burgess², and Christopher C. Broder^{1*}

10
11
12
13
14
15

Table S1. β -CoV MMIA performance

		SARS-CoV-2 PCR Status/Archival Sera		
		Positive	Negative	Total
SARS-CoV-2 spike IgM Antibody Test	Positive	110	0	110
	Negative	40	84	124
	Total	150	84	234
	Sensitivity	73.33%		
	Specificity	100.00%		

16

Table S2. IgG and IgM seropositivity within 28 days post-symptom onset (dps)

dspo	IgG+	IgG+/IgM+
7 – 14	80.0% (12/15)	73.3% (11/15)
15 – 28	100% (31/31)	93.5% (29/31)

18
19
20
21
22
23
24
25
26

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48




Figure S1. 99.7% probability distribution threshold cutoffs for SARS-CoV-2 antigen

reactive IgG. Convalescent serum samples (n=43) from SARS-CoV-2 naïve ARIC subjects with HCoV PCR-confirmed infections were tested with MMIA indicated in panels. Antigens shown as follows: **(A)** SARS-CoV-2 spike (S-2P), **(B)** SARS-CoV-2 spike (S-2P), **(C)** SARS-CoV-2 RBD, and **(D)** SARS-CoV-2 NP; sold lines indicate the mean+3SD (99.7%) MFI.

49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69




Figure S2. Receiver operating characteristic (ROC) curve analysis of SARS-CoV-2 PCR-positive and -negative serum samples from the EPICC study provided a second measurement of threshold cutoffs for SARS-CoV-2 antigen reactive IgG. EPICC Sera were tested with MMIA indicated in panels; antigens shown as follows: (A) SARS-CoV-2 spike (S-2P), (B) SARS-CoV-2 spike (S-2P), (C) SARS-CoV-2 RBD, and (D) SARS-CoV-2 N

70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94




Figure S3. SARS-CoV-2 spike reactive IgM detection with the β -CoV MMIA.

(A) ROC curve analysis of SARS-CoV-2 spike protein IgM antibody reactivity in a β -CoV MMIA. PCR-confirmed SARS-CoV-2 positive and negative serum samples (n= 105) were tested and 100% specificity was achieved at threshold cutoff of 1446 MFI. **(B)** SARS-CoV-2 naïve ARIC HCoV PCR-positive convalescent serum samples (n=43) were tested to establish a 99.7% probability threshold (840 MFI). **(C)** ARIC (n=84), SARS-CoV-2 PCR-positive EPICC (n=116) and JMS (n=35) serum samples were tested in technical duplicates.